The proteomic test identifies prostate cancer patients with likely non-aggressive forms of the disease that can be treated without surgery or radiation therapy.
The insurer will cover Metamark's urology specialized diagnostics throughout the state.
The deal is the latest coverage and reimbursement success for the Cambridge, Massachusetts-based urology diagnostics firm.
Medicare contractors Palmetto GBA, Noridian Healthcare Solutions, and CGS Administrators have all proposed reimbursement coverage for the ProMark test.
The companies have also agreed to co-develop a second-generation version of the assay, which will run on Hologic's Panther instrument system.
The study, by Fred Hutchinson researchers consulting with Metamark, found the test offers increased quality-adjusted life-years and a decrease in costs.
The funding will be used to further expand the company's clinical testing products and services in the US and abroad.
The deal provides access to Metamark's diagnostic and prognostic tests for urology to 5.2 million Highmark Blue Shield members in Delaware, Pennsylvania, and West Virginia.
Since launching it in June, the firm has sold roughly 1,000 tests. It measures eight proteins to determine the likelihood that a patient's cancer is aggressive.
The laboratory will serve as the primary processor for the company's protein-based prostate cancer test called ProMark.
Australia will not be regulating gene editing of plants, animals, and human cell lines as long as no new genetic material is incorporated, reports Nature News.
The Washington Post reports that the US Department of Agriculture told its researchers to label peer-reviewed articles as "preliminary" work.
Researchers have sequenced the genomes of both the coast redwood and the giant sequoia, according to the San Francisco Chronicle.
In PNAS this week: study of epigenetic patterns in mammalian eggs, clonal expansion patterns in CD8+ T cells, and more.